Vimarsana
Biggest News Aggregation in the World

Miguel Saps News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Miguel Saps. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Miguel Saps Today - Breaking & Trending Today

Ironwood Announces Publication in The Lancet Gastroenterology & Hepatology of New Linaclotide Phase III Data in Children and Adolescents Aged 6-17 Years with Functional Constipation - Vimarsana News

Ironwood Announces Publication in The Lancet Gastroenterology & Hepatology of New Linaclotide Phase III Data in Children and Adolescents Aged 6-17 Years with Functional Constipation

Published: January 9, 2024

– Newly published data highlights additional efficacy endpoints from trial – – Linaclotide is the first and only FDA-approved prescription therapy for children and adolescents aged 6-17 years...

Source: marketscreener.com
Related Topics:
United StatesGeorgee BatchelorIronwood Pharmaceuticals NasdaqJerome FoundationUniversity Of Miami Health SystemUniversity Of MiamiIronwood Pharmaceuticals IncNational Population Projection TablesDrug AdministrationDivision Of Pediatric GastroenterologyIronwood PharmaceuticalsLancet GastroenterologyMiguel SapsPediatric GastroenterologyEndowed ChairMiami HealthCommon Adverse ReactionsPrescribing InformationBoxed WarningChildhood Functional Gastrointestinal DisordersFunctional Gastrointestinal DisordersPopulation Projection TablesFunctional Defecation DisordersSystemic Review
New Phase 3 Data Reinforces Safety, Efficacy of Linaclotide for Pediatric Functional Constipation - Vimarsana News

New Phase 3 Data Reinforces Safety, Efficacy of Linaclotide for Pediatric Functional Constipation

Published: January 9, 2024

The new data was published in The Lancet Gastroenterology & Hepatology and highlighted additional efficacy endpoints from the study used to support linaclotide’s FDA approval in 2023.

Source: hcplive.com
Related Topics:
Georgee BatchelorMichael ShetzlineDrug AdministrationUniversity Of MiamiIronwood Pharmaceuticals AnnouncesIronwood PharmaceuticalsUniversity Of Miami Health System Miguel SapsMiami Health SystemMiguel SapsLancet GastroenterologyEndowed ChairBristol Stool Form ScaleIronwood Announces PublicationNew Linaclotide PhaseAdolescents AgedNew IndicationFunctional ConstipationPediatric Patients AgesChronic Idiopathic ConstipationIrritable Bowel SyndromeBowel Movement
Ironwood to Present New Data at Digestive Disease Week® 2023 Demonstrating Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old - Vimarsana News

Ironwood to Present New Data at Digestive Disease Week® 2023 Demonstrating Potential of Linaclotide for Functional Constipation in Children and Adolescents Ages 6-17 Years-Old

Published: April 24, 2023

– Pivotal Phase III data will be spotlighted via an oral presentation – – Additional efficacy and safety data will be featured across four posters – ... | June 18, 2023

Source: marketscreener.com
Related Topics:
United StatesNew YorkHong KongUniversity Of MiamiTime ToJeffrey Samuel HyamsAstra ZenecaJulie KhlevnerSamuel NurkoConnecticut Children Medical CenterIronwood PharmaceuticalsDrug AdministrationIronwood Pharmaceuticals IncIronwood Pharmaceuticals NasdaqJerome FoundationDisease WeekPriority ReviewNew Drug ApplicationPrescription Drug User Fee ActPediatric FunctionalTreating Functional ConstipationPediatric Patients AgedPlacebo Controlled TrialCarlo Di LorenzoNationwide Children